EcoDrugPlus

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSOKIG00005010783
Gene Symbol: AVPR1A
3 Cross references
187 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSOKIG00005020657
Gene Symbol: AVPR2
3 Cross references
172 Possible Orthologues:

Aryl Hydrocarbon Receptor

Ensembl ID : ENSOKIG00005049511
Gene Symbol: LOC109884603
3 Cross references
152 Possible Orthologues:

Aryl Hydrocarbon Receptor 1a

Ensembl ID : ENSOKIG00005044071
Gene Symbol: AHR1A
1 Cross references
152 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 1

Ensembl ID : ENSOKIG00005016734
Gene Symbol: LOC109875808
3 Cross references
186 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 1-Like

Ensembl ID : ENSOKIG00005014373
Gene Symbol: LOC109901951
2 Cross references
185 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 3-Like

Ensembl ID : ENSOKIG00005014251
Gene Symbol: LOC109875913
3 Cross references
206 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 3-Like

Ensembl ID : ENSOKIG00005000147
Gene Symbol: LOC109880156
3 Cross references
204 Possible Orthologues:

Aurora Kinase B

Ensembl ID : ENSOKIG00005050742
Gene Symbol: LOC109867393
3 Cross references
199 Possible Orthologues:

Aurora Kinase B

Ensembl ID : ENSOKIG00005021484
Gene Symbol: AURKB
3 Cross references
200 Possible Orthologues:

Aurora Kinase C

Ensembl ID : ENSOKIG00005026781
Gene Symbol: LOC109899692
3 Cross references
233 Possible Orthologues:

Bcl-2-Like Protein 1

Ensembl ID : ENSOKIG00005031838
Gene Symbol: LOC109907974
3 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).